BIOMAT Database Logo BIOMAT Database Logo

Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. 2004

Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. hiroshi.fukushima@po.rd.taisho.co.jp

Dipeptidyl peptidase IV (DPP-IV) inhibitors have attracted attention as potential drugs for use in the treatment of type 2 diabetes because they prevent degradation of glucagon-like peptide-1 (GLP-1) and extend its duration of action. A series of 2-cyanopyrrolidines are among the most potent of DPP-IV inhibitors. We focused our attention on substitutions at the 3- or 4-position of 2-cyanopyrrolidines and synthesized and evaluated various derivatives. Among them, the 4-fluoro derivative was found to exhibit better DPP-IV inhibitory activity and higher plasma drug concentrations after oral administration to rats than the 4-unsubstituted derivative. We report here on the synthesis and biological data of the aforementioned derivatives.

UI MeSH Term Description Entries
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
June 2006, Journal of medicinal chemistry,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
August 2013, Chemical biology & drug design,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.
January 2004, Bioorganic & medicinal chemistry letters,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors.
June 2006, Bioorganic & medicinal chemistry letters,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Dipeptidyl peptidase IV inhibitors with the N-terminal MXP sequence: structure-activity-relationships.
January 2003, Advances in experimental medicine and biology,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.
March 1999, Journal of medicinal chemistry,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors.
March 2013, Bioorganic & medicinal chemistry letters,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.
April 2007, Journal of medicinal chemistry,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
September 2004, Bioorganic & medicinal chemistry letters,
Hiroshi Fukushima, and Akira Hiratate, and Masato Takahashi, and Masako Saito, and Eiji Munetomo, and Kiyokazu Kitano, and Hidetaka Saito, and Yuji Takaoka, and Koji Yamamoto
Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors.
February 2004, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!